A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.
about
Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyRecipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantationPopulation pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipientsAssociation of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipientsA limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipientsPopulation pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients.Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model.Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioningPopulation pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
P2860
Q33827819-DAF27062-0FCE-4908-9EA9-FB61FB1AA358Q34175259-5C94F1F8-3899-40C2-8E8E-FA4D93C327C7Q34807259-3266B12B-7377-49B8-8CF9-2213A2F52FCFQ35760706-0D43F56F-EDBD-4CFC-94D7-C187DB638699Q35811940-E63B814B-6294-40F6-9294-8F86DAA7BFAFQ35843096-66C387D4-C3B0-4A44-BF8C-22824C26AB12Q36728151-0BCC9049-FC66-4910-9C6D-F98DA36B9FFAQ37206443-AFB7570A-515B-4247-8698-8F6833744B2AQ38262916-424C6636-F68E-4493-913E-0F47FE730FB1Q38374457-F8A91181-8E38-4DA3-89AA-24572F6A0385Q39746660-B5BD0C0D-5259-45F9-B95F-2D4A5583BC07Q40791419-2FB7ABD2-0C57-4C60-9CD2-925D40E40A47Q43418954-08D07482-AA44-4377-AD62-5AF8544C3B7DQ48106141-354C6CEB-B56F-40A1-A860-1C1735695761
P2860
A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A limited sampling schedule to ...... etic cell transplant patients.
@en
A limited sampling schedule to ...... etic cell transplant patients.
@nl
type
label
A limited sampling schedule to ...... etic cell transplant patients.
@en
A limited sampling schedule to ...... etic cell transplant patients.
@nl
prefLabel
A limited sampling schedule to ...... etic cell transplant patients.
@en
A limited sampling schedule to ...... etic cell transplant patients.
@nl
P2093
P2860
P1476
A limited sampling schedule to ...... etic cell transplant patients.
@en
P2093
Claudio Anasetti
David H Salinger
David K Blough
Paolo Vicini
Paul V O'Donnell
P2860
P304
P356
10.1158/1078-0432.CCR-09-0427
P407
P577
2009-08-11T00:00:00Z